Descripción de negocio
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases.
Consejo de gestión & Consejo de supervisión
| CEO |
| Dr. Osamu Okuda |
| Consejo de gestión |
| Toshiaki Itagaki |
| Consejo de supervisión |
| Dr. Osamu Okuda, Dr. Hisafumi Yamada, Toshiaki Itagaki, Dr. Mariko Y Momoi, Dr. Fumio Tateishi, Hideo Teramoto, Dr. Christoph Franz, Dr. James H. Sabry, Teresa A. Graham |
Datos de la empresa
| Nombre: |
Chugai Pharmaceutical Co., Ltd. |
| Dirección: |
1-1 Nihonbashi-Muromachi 2-Chome Chuo-ku,Tokyo 103-8324 |
| Teléfono: |
+81-(0)3-3281-6611 |
| Fax: |
+81-(0)3-3281-6607 |
| E-mail: |
-
|
| Internet: |
https://www.chugai-pharm.co.jp/english/index.html |
| Industria: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Subsector: |
- |
| Fin del año financiero: |
31/12 |
| Acciones de libre circulación: |
- |
| Fecha de OPI: |
- |
Relación con inversores
| Nombre: |
- |
| IR teléfono: |
+81-(0)3-3273-0554 |
| IR-fax: |
+81-(0)3-3281-6607 |
| IR e-mail: |
-
|
